Skip to content

Study on the Efficacy and Mechanism of Accelerated Deep Intermittent Theta Burst Stimulation for Treatment-Resistant Late-Life Depression

Study on the Efficacy and Mechanism of Accelerated Deep Intermittent Theta Burst Stimulation for Treatment-Resistant Late-Life Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108248
Enrollment
Unknown
Registered
2025-08-27
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment resistant late life depression

Interventions

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age>=60 years old; 2. Meet the diagnostic criteria for depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5); 3. The total score of HAMD-17 >=17 points; 4. Sufficient doses of antidepressants with two different mechanisms in the past were ineffective. Patients had good medication adherence at the minimum or maximum tolerated dose, and the duration of each drug was not less than 4 weeks [42]. 5. Primary school education level or above, able to cooperate with the completion of the assessment and inspection; 6. Obtain written informed consent from the person or his family.

Exclusion criteria

Exclusion criteria: 1. Previous history of head disease, brain injury, seizures and other neurological diseases; 2. Have serious or unstable cardiovascular, respiratory, immune or other system diseases; 3. Past or current DSM-5 diagnosis of the following mental illnesses: organic mental disorder, Alzheimer's disease, secondary dementia caused by other causes, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder, undefined mental illness, alcohol (or drug) dependence or abuse, personality disorder; 4. Contraindications to MRI or transcranial magnetic therapy: such as electronic or metal implants (dentures, arterial clips, pacemakers or metal fixtures, etc.), claustrophobia, etc.; 5. Participated in interventional clinical trials in the previous 3 months before screening; 6. Pregnant, lactating women or those planning to become pregnant.

Design outcomes

Primary

MeasureTime frame
Montgomery-Asberg depression rating scale,MADRS;

Secondary

MeasureTime frame
17-item Hamilton depression scale,HAMD-17;Hamilton anxiety rating scale,HAMA;Pittsburgh sleep quality index,PSQI;the geriatric depression scale,GDS;repeatable battery for the assessment of neuropsychological status,RBANS;Montreal cognitive assessment,MoCA;brain MRI;

Countries

China

Contacts

Public ContactQinge Zhang

Beijing Anding Hospital, Capital Medical University

zqe81@126.com+86 10 5830 3007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026